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Background: The percentage of tumour stroma (TSP) has recently been reported to be a novel independent predictor of
outcome in patients with a variety of common solid organ tumours. The aim of this study was to examine the relationship between
TSP, clinicopathological characteristics and outcome in patients with invasive ductal breast cancer, in particular node negative and
triple negative disease.
Methods: A total of 361 patients with primary operable invasive ductal breast cancer were included in this study. The TSP was
assessed visually on the haematoxylin and eosin-stained tissue sections. With a cutoff value of 50% TSP, patients with p50%
stroma were classified as the low-TSP group and those with 450% stroma were classified as the high-TSP group.
Results: A total of 109 (30%) patients had high TSP. Patients with high TSP were old age (P¼ 0.035), had more Her-2-positive
tumours (P¼ 0.029), low-grade tumour inflammatory infiltrate (P¼ 0.034), low CD68þmacrophage infiltrate (Po0.001), low CD4þ
(P¼ 0.023) and low CD8þ T-lymphocytes infiltrate (P¼ 0.017), tumour recurrence (P¼ 0.015) and shorter cancer-specific survival
(Po0.001). In node-negative patients (n¼ 207), high TSP was associated with low CD68þmacrophage infiltrate (P¼ 0.001), low
CD4þ (P¼ 0.040) and low CD8þ T-lymphocytes infiltrate (P¼ 0.016) and shorter cancer-specific survival (P¼ 0.005). In triple
negative patients (n¼ 151), high TSP was associated with high tumour grade (P¼o0.001), lymph node positivity (P¼ 0.027), low
CD68þmacrophage infiltrate (P¼ 0.011) and shorter cancer-specific survival (P¼ 0.035). The 15-year cancer-specific survival rate
was 79% vs 21% in the low-TSP group vs high-TSP group. In multivariate survival analysis, a high TSP was associated with reduced
cancer-specific survival in the whole cohort (P¼ 0.001), node-negative patients (P¼ 0.007) and those who received systemic
adjuvant therapy (P¼ 0.021), independent of other pathological characteristics including host inflammatory response. However,
TSP was not an independent prognostic factor for triple negative patients (P¼ 0.151).
Conclusions: A high TSP in primary operable invasive ductal breast cancer was associated with recurrence and poorer long-term
survival. The inverse relation with the tumour inflammatory infiltrate highlights the importance of the amount of tumour stroma
on immunological response in patients with primary operable ductal breast cancer. Implementing this simple and reproducible
parameter in routine pathological examination may help optimise risk stratification in patients with invasive ductal breast
cancer.
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Breast cancer is the commonest cancer and the leading cause of
cancer death in women. It accounts for approximately 10th of all
new cancers and 25% of all female cancers (Ferlay et al, 2010).
With the advent of a screening programme, more than 70% of
newly diagnosed invasive tumours present without nodal involve-
ment (Health and Consumer Protection Directorate-General,
2006) and those women have 88% 10-year disease-free survival
rate (Mirza et al, 2002).
In recent years, the simple concept that tumour progression
depends solely on the intrinsic properties of cancer cells has
recently given way to a more complex paradigm in which tumour
progression depends on the interaction between tumour and host
cells (Colotta et al, 2009; Hanahan and Weinberg, 2011). Recent
evidence suggests that the tumour stroma profoundly influences
tumour growth, angiogenesis and dissemination. Tumour stroma is
thought to promote tumourigenesis by different mechanisms
including remodelling of the extracellular matrix, suppression of
immune response and alterations in stromal regulatory pathways
affecting the motility and aggressiveness of cancer cells (Kim et al,
2005; Hu and Polyak, 2008; Cirri and Chiarugi, 2012).
Recently, it has been reported that tumour stroma has
prognostic value in patients with colorectal (Mesker et al, 2007;
West et al, 2010; Huijbers et al, 2013, Park et al, 2014) and
oesophageal cancers (Staal et al, 2010; Wang et al, 2012). Also, the
percentage of tumour stroma has been recently reported to have
prognostic value in patients with triple negative (de Kruijf et al,
2011; Moorman et al, 2012) and node-negative breast cancer
(Dekker et al, 2013). However, the relationship with other
important determinants of outcome such as the lymphovascular
invasion, necrosis and tumour inflammatory cell infiltrate is
unclear.
Therefore, the aim of this study was to examine the relationship
between the percentage of tumour to stroma, host inflammatory
response, clinicopathological characteristics and outcome in
patients with early breast cancer, in particular node negative and
triple negative disease.
MATERIALS AND METHODS
Patients. Patients presenting with primary operable invasive
ductal breast cancer at Royal Infirmary, Western Infirmary and
Stobhill Hospital, Glasgow, between 1995 and 1998 were studied
(n¼ 361). Clinicopathological data including age, histological
tumour type, grade, tumour size, lymph node status, type of
surgery and use of adjuvant treatment (chemotherapy, hormonal
therapy and/or radiotherapy) were retrieved from the routine
reports. ER, PR and Her-2 status were performed as previously
described and the results of visual scoring were used in this study
(Mohammed et al, 2012a,b). Tumour necrosis, general inflamma-
tory infiltrate, CD68þmacrophage infiltrate, CD4þT-lympho-
cyte infiltrate, CD8þT-lymphocyte infiltrate were performed as
previously described (Ikpatt et al, 2002; Klintrup et al, 2005;
Mohammed et al, 2012c,2013). Ki67 was performed as previously
described (Mohammed et al, 2012d).
In the present study, the proportion of patients with ER-
negative tumours was relatively high in the TMA. This enabled
specific examination of the prognostic value of tumour character-
istics in a sub-cohort of patients with ER-negative ductal breast.
Also, the patients included in this study did not receive
neoadjuvant therapy or adjuvant anti-HER-2 therapy. The
inclusion of ductal breast cancers only was to limit the potential
confounding effects of other tumour types on the analysis in the
present study.
Patients were routinely followed up following surgery. Date and
cause of death was cross-checked with the cancer registration
system and the Registrar General (Scotland). Death records were
complete until 31st of May 2013 and that served as the censor date.
Cancer recurrence was measured from the date of primary surgery
until the date of first recurrence of breast cancer. Cancer-specific
survival was measured from the date of primary surgery until the
date of death from breast cancer.
Institutional Review Board approval for the use of human tissue
in this study was given by the Research Ethics Committee of the
North Glasgow University Hospitals NHS Trust.
Slide scanning and assessment of tumour stroma. The haema-
toxylin and eosin tumour sections stained according to standard
histological protocols were scanned using a Hamamatsu Nano-
Zoomer (Welwyn Garden City, Hertfordshire, UK) at objective
magnification  20. Visualisation and image analysis assessment
was carried out using Slidepath Digital Image Hub, version 4.0.1,
(Slidepath, Leica Biosystems, Milton Keynes, UK). Visual assess-
ment of TSP was performed on a high-definition monitor and was
carried out at the most invasive tumour area according to
previously described criteria (Mesker et al, 2007). As Slidepath
provides different levels of magnification similar to a conventional
microscope, the most invasive tumour area to be analysed was
identified visually and selected using a  4 or  5 magnification.
The magnification was then set to  10 at the selected area where
both stroma and tumour tissue were available. Tumour cells must
be present at all borders of the image field (north–east–south–
west) (Figure 1). When necrotic and mucinous tissue was present
within the selected area, the mucinous tissue was visually excluded
for the scoring. Scoring percentages were given per 10-fold (10, 20,
30% etc.).
Cutoff at 50% TSP was used as described in previous reports
(Mesker et al, 2007; de Kruijf et al, 2011) i.e., low stroma tumours
100 m 100 m
Figure 1. Haematoxylin and eosin-stained sections of invasive ductal breast tumours. (A) Tumour with low stroma (10%); (B) tumour with high
stroma (80%). Magnificatiom 10 objective and 100-mm scale.
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were the presence of tumour stroma in p50% of tumour area
(Figure 1A), whereas high stroma tumours were the presence of
tumour stroma in 450% of tumour area (Figure 1B).
A total of 40 specimens were independently estimated for TSP
by two observers (FJAG and JE) blinded to the patient outcome
and the other observer’s score. The ICCC was 0.83 indicating
excellent agreement. The author (FJAG) then scored the rest of
slides.
Statistical analysis. Consistency between the observers was
analysed using the ICCC value. Inter-relationships between
variables were assessed using contingency table analysis with the
w2 test for trend as appropriate. Univariate and multivariate
survival analysis were performed using the Kaplan–Meier analysis
and Cox proportional hazards model. A stepwise backward
procedure was used to derive a final model of the variables that
had a significant independent relationship with survival. All
statistical analyses were two-sided and significance defined as
P-value o0.05. Deaths up to May 2013 were included in the
analysis. All statistical analysis was performed using the SPSS
software version 19 (SPSS Inc., Chicago, IL, USA).
RESULTS
Clinicopathological characteristics. Table 1 shows clinicopatho-
logical characteristics of patients (n¼ 361). The majority were
older than 50 years (65%), had a grade III carcinoma (54%) equal
or smaller than 2 cm (51%) with no axillary lymph node
involvement (57%). The majority had ER-negative tumours
(54%), PR-negative tumours (66%) and Her2-negative tumours
(80%). A total of 30% had lymphovascular invasion and the
majority had a high-grade tumour necrosis (64%). In total, 60%
had low-grade general tumour inflammatory infiltrate with the
cellular inflammatory infiltrates (CD68þmacrophage infiltrate,
CD4þT-lymphocyte infiltrate and CD8þT-lymphocyte infil-
trate) presented as tertiles (Table 1). In all, 81 (22%) patients
received only hormonal therapy, 144 (40%) received only
chemotherapy and 45 (13%) received both, and data on seven
cases were not available.
The minimum follow-up of survivors was 142 months and the
median follow-up was 168 months. During follow-up, 89 patients
developed recurrence (25%), 172 patients died, 27% died of their
cancer.
TSP. For all patients, TSP was evaluated on one section derived
from the most invasive part of the tumour. The tumour specimens
showed variety in TSP ranging from very solid tumours with little
stromal involvement (Figure 1A) to tumours with large areas of
stromal proliferation scattered with single and grouped tumour
cells (Figure 1B). In total, 252 (70%) patients had low TSP (p50%
stroma) and 109 (30%) patients had high TSP (450% stroma).
In node-negative patients, 153 (74%) patients had low TSP and 54
(26%) had high TSP. In triple negative patients, 115 (76%) patients
had low TSP and 36 (24%) had high TSP.
Association of TSP with clinicopathological variables and
outcome. The relationship between TSP, clinicopathological
variables and host inflammatory response is shown in Tables 2–4.
Patients with high TSP were old age women (P¼ 0.035),
had more Her-2-positive tumours (P¼ 0.029), low-grade general
inflammatory infiltrate (P¼ 0.034), low CD68þmacrophage
infiltrate (Po0.001), low CD4þ (P¼ 0.023) and low CD8þ
T-lymphocytes infiltrate (P¼ 0.017), had tumour recurrence
(P¼ 0.015) and shorter cancer-specific survival (P¼ 0.001). In
node-negative patients (n¼ 207), a high TSP was associated with
low CD68þmacrophage infiltrate (P¼ 0.001), low CD4þ
(P¼ 0.040) and low CD8þ T-lymphocytes infiltrate (P¼ 0.016)
and shorter cancer-specific survival (P¼ 0.005). In triple negative
patients (n¼ 151), a high TSP was strongly associated with high
tumour grade (P¼o0.001), lymph node positivity (P¼ 0.027),
low CD68þmacrophage infiltrate (P¼ 0.011), low CD4þ
(P¼ 0.049) and tended to have low CD8þ T-lymphocytes
infiltrate (P¼ 0.071) and shorter cancer-specific survival
Table 1. The clinicopathological characteristics of patients with early breast cancer (n¼ 361)
Clinicopathological characteristics Patients (n)
Age (p50/450 years) 125 (35%) / 236 (65%)
Size (p20/21–50/450mm) 185 (51%) / 163 (45%) / 13 (4%)
Grade (I/II/III) 48 (13%) / 124 (34%) / 189 (52%)
Involved lymph node (0/1–3/43) 207 (57%) / 120 (33%) / 34 (9%)
Oestrogen receptor status (no/yes) 194 (54%) / 167 (46%)
Progesterone status (no/yes) 238 (66%) / 123 (34%)
Her-2 status (no/yes) 290 (80%) / 71 (20%)
Lymphovascular invasion (no/yes) 251 (70%) / 110 (30%)
Tumour necrosis (no/yes) 131 (36%) / 230 (64%)
General inflammatory infiltrate (low/high) 215 (60%) / 146 (40%)
CD68þmacrophage infiltrate (tertiles) 82 (23%) / 115 (32%) / 103 (29%) / 61 (17%)a
CD4þT-lymphocyte infiltrate (tertiles) 132 (37%) / 112 (31%) / 117 (32%)
CD8þT-lymphocyte infiltrate (tertiles) 121 (34%) / 118 (33%) / 122 (34%)
Tumour stroma percentage (p50%/450%) 252 (70%) / 109 (30%)
Loco-regional therapy (Lumpectomyþ radiotherapy/mastectomyþ radiotherapy) 130 (36%) / 231 (64%)
Systemic adjuvant therapy (hormonal/hormonalþ chemotherapy/chempotherapy/none) 81 (22%) / 45 (13%) / 144 (40%) / 84 (23%) / 7 (2%)a
Tumour recurrence (no/yes) 272 (75%) / 89 (25%)
Alive/cancer death/non-cancer death 189 (52%) / 97 (27%) / 75 (21%)
aNumber of patients when incomplete data available.
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Table 2. The inter-relationship between clinicopathological characteristics and tumour stroma percentage in patients with invasive ductal breast cancer
(n¼361)
Tumour stroma
percentagep50 n¼252 (70%)
Tumour stroma
percentage450 n¼109 (30%) P-value
Age (p50/450 years) 96/156 29/80 0.035
Size (p20/21–50/450mm) 136/108/8 49/55/5 0.109
Grade (I/II/III) 35/77/140 13/47/49 0.289
Involved lymph node (0/1–3/43) 153/78/21 54/42/13 0.052
Oestrogen receptor status (no/yes) 138/114 56/53 0.554
Progesterone status (no/yes) 168/84 70/39 0.653
Her-2 status (no/yes) 210/42 80/29 0.029
Lymphovascular invasion (no/yes) 180/72 71/38 0.234
Tumour necrosis (no/yes) 91/161 40/69 0.915
General inflammatory infiltrate (low/high) 141/111 74/35 0.034
CD68þmacrophage infiltrate (tertiles) 40/84/80 42/31/23 o0.001
CD4þT-lymphocyte infiltrate (tertiles) 66/111/75 36/54/19 0.023
CD8þT-lymphocyte infiltrate (tertiles) 71/80/101 73/46/26 0.017
Loco-regional therapy (Lumpectomyþ radiotherapy/
mastectomyþ radiotherapy)
93/159 37/72 0.591
Systemic adjuvant therapy (hormonal/hormonalþ
chemotherapy/chempotherapy/none)
55/35/97/61 30/21/35/23 0.104
Tumour recurrence (no/yes) 199/53 73/36 0.015
Alive/cancer death/non-cancer death 151/55/46 38/42/29 o0.001
Cancer-specific survival (months)a 176(168–186) 144(128–160) o0.001
aMean (95% confidence interval).
Table 3. The inter-relationship between clinicopathological characteristics and tumour stroma percentage in node-negative patients (n¼ 207)
Tumour stroma percentage
(p50) n¼153 (74%)
Tumour stroma percentage
(450) n¼54 (26%) P-value
Age (p50/450 years) 54/99 13/41 0.131
Size (p20/21–50/450mm) 90/60/3 30/23/1 0.709
Grade (I/II/III) 26/45/82 8/28/18 0.123
Oestrogen receptor status (no/yes) 84/69 26/28 0.394
Progesterone status (no/yes) 103/50 35/19 0.738
Her-2 status (no/yes) 128/25 41/13 0.208
Lymphovascular invasion (no/yes) 123/25 41/13 0.488
Tumour necrosis (no/yes) 62/91 21/33 0.488
General inflammatory infiltrate (low/high) 89/64 39/15 0.068
CD68þmacrophage infiltrate (tertiles) 27/49/46 24/13/10 0.001
CD4þT-lymphocyte infiltrate (tertiles) 36/67/50 17/28/9 0.040
CD8þT-lymphocyte infiltrate (tertiles) 41/52/60 22/20/12 0.016
Recurrence status (no/yes) 130/23 41/13 0.133
Loco-regional therapy (Lumpectomyþ radiotherapy/
mastectomyþ radiotherapy)
65/88 24/30 0.803
Systemic adjuvant therapy (hormonal/hormonalþ
chemotherapy/ chemotherapy/none)
35/12/55/49 15/8/16/15 0.251
Alive/cancer death/non-cancer death 102/20/31 124/35/48 0.002
Cancer-specific survival (months)a 192 (183–201) 164 (144–184) 0.005
aMean (95% confidence interval).
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(P¼ 0.035). A high TSP was not associated with hormonal status,
tumour necrosis and lymphovascular invasion.
Sub-group analysis of the relationship between the TSP and
Ki67 in different patient groups was performed (Table 5). Only
59% of patients from the whole cohort, 44% from node-negative
group and 65% from triple negative group had Ki67 information
available. There was no significant statistical difference between
high-TSP and low-TSP groups in all sub-cohorts.
The 15-year cancer-specific survival rate was 79% vs 21% in the
low-TSP group vs high-TSP group. Kaplan–Meier survival curves
show that high TSP was significantly associated with poorer
cancer-specific survival in the whole cohort (Po0.001), in node-
negative patients (P¼ 0.005) and in triple negative patients
(P¼ 0.035) (Figures 2A–C). In multivariate survival analysis, a
high TSP was associated with reduced cancer-specific survival
independent of other variables in the whole cohort (HR 2.12, 95%
CI 1.37–3.29, P¼ 0.001) and in node-negative patients (HR 3.11,
95% CI 1.53–6.33, P¼ 0.007) but not in triple negative patients
(P¼ 0.151) (Tables 6–8).
The relationship between TSP, clinicopathological character-
istics and survival in patients who underwent adjuvant systemic
treatment was examined. In total, 270 (75%) patients received
adjuvant systemic treatment. A high TSP was associated with
shorter cancer-specific survival following adjuvant treatment in
univariate analysis (HR 2.04, 95% CI 1.29–3.22, P¼ 0.002). In
multivariate analysis, a high TSP was associated with reduced
cancer-specific survival (HR 1.86, 95% CI 1.10–3.15, P¼ 0.021),
independent of PR status, lymph node involvement, tumour
necrosis and CD68þT-lymphocyte infiltrate.
DISCUSSION
The results of the present study show that high TSP was
consistently associated with low tumour inflammatory infiltrate.
Furthermore, TSP was associated with poorer outcome in the
whole cohort and in patients with node-negative disease with long-
term follow-up. Taken together, the present results highlight the
importance of the stroma in the tumour microenvironment and its
impact on outcome.
Consistent with previous reports, the role of tumour stroma in
breast cancer (de Kruijf et al, 2011; Moorman et al, 2012; Dekker
et al, 2013) survival in the present study was significantly shorter in
patients with high-TSP tumours. However, TSP was not indepen-
dently associated with survival in triple negative patients, whereas
de Kruijf et al (2011) reported that TSP was indeed a significant
prognostic factor. The difference between these findings might be
attributed to the differences in patients’ characteristics or might be
Table 4. The inter-relationship between clinicopathological characteristics and tumour stroma percentage in triple negative patients with invasive ductal
breast cancer (n¼151)
Tumour stroma
percentagep50 n¼115 (76%)
Tumour stroma
percentage450 n¼36 (24%) P-value
Age (p50/450 years) 49/66 14/22 0.694
Size (p20/21–50/450mm) 62/49/4 15/18/7 0.127
Grade (I/II/III) 0/17/98 3/11/22 o0.001
Involved lymph node (0/1–3/43) 68/30/10 15/20/8 0.027
Lymphovascular invasion (no/yes) 77/38 20/16 0.214
Tumour necrosis (no/yes) 28/87 9/27 0.931
General inflammatory infiltrate (low/high) 44/71 19/17 0.124
CD68þmacrophage infiltrate (tertiles) 19/28/36 14/5/7 0.011
CD4þT-lymphocyte infiltrate (tertiles) 19/48/48 11/15/10 0.049
CD8þT-lymphocyte infiltrate (tertiles) 25/34/56 11/14/11 0.071
Tumour recurrence (no/yes) 83/32 21/15 0.119
Loco-regional therapy (Lumpectomyþ radiotherapy/
mastectomyþ radiotherapy)
41/74 18/18 0.125
Systemic adjuvant therapy (hormonal/hormonalþ
chemotherapy/chempotherapy/none)
13/7/67/25 6/4/19/7 0.296
Alive/cancer death/non-cancer death 64/33/18 13/16/7 0.103
Cancer-specific survival (months)a 176 (167–185) 147 (133–163) 0.035
aMean (95% confidence interval).
Table 5. The inter-relationship between tumour stroma percentage and Ki67 in patients with invasive ductal breast cancer
All patients (n¼214)
Tumour stroma percentagep50
n¼115 (76%)
Tumour stroma percentage450
n¼36 (24%) P-value
Ki67 (low/high) 122/27 54/11 0.833
Node-negative patients (n¼120) 89 (74%) 31 (26%)
Ki67 (low/high) 75/14 28/3 0.407
Triple negative patients (n¼99) n¼76 (77%) n¼ 23 (23%)
Ki67 (low/high) 61/15 19/4 0.803
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Figure 2. Kaplan–Meier survival curves Kaplan–Meier survival curves (log rank) of cancer-specific survival for tumour stroma percentage in the
whole cohort (A), Node-negative patients (B) and triple negative patients (C).
Table 6. The relationship between clinicopathological characteristics and cancer-specific survival in patients with invasive ductal breast cancer (n¼ 361)
Univariate analysis Multivariate analysis
Hazard ratio (95%
confidence interval) P-value
Hazard ratio (95%
confidence interval) P-value
Age (p50/450 years) 0.97 (0.64–1.46) 0.881
Size (p20/21–50/450mm) 2.17 (1.54–3.07) o0.001 0.142
Grade (I/II/III) 1.85 (1.3–2.58) o0.001 1.72 (1.18–2.51) 0.005
Involved lymph node (0/1–3/43) 1.97 (1.51–2.56) o0.001 1.97 (1.46–2.66) o0.001
Oestrogen receptor status (no/yes) 0.52 (0.34–0.79) 0.002 0.240
Progesterone status (no/yes) 0.44 (0.32–0.82) 0.006 0.184
Her2 status (no/yes) 1.44 (0.88–2.35) 0.145
Lymphovascular invasion (no/yes) 2.07 (1.39–3.09) o0.001 0.864
Tumour necrosis (no/yes) 1.97 (1.29–2.99) 0.002 2.49 (1.42–4.39) 0.001
General inflammatory infiltrate (low/high) 1.15 (0.77–1.73) 0.482
CD68þT-lymphocyte infiltrate (tertiles) 0.73 (0.55–0.96) 0.025 0.174
CD4þT-lymphocyte infiltrate (tertiles) 0.46 (0.23–1.70) 0.075
CD8þT-lymphocyte infiltrate (tertiles) 0.64 (0.49–0.82) o0.001 0.66 (0.46–0.80) 0.002
Loco-regional therapy (Lumpectomyþ radiotherapy/
mastectomyþ radiotherapy)
2.01 (1.27–3.19) 0.003 0.535
Systemic adjuvant therapy (hormonal/hormonalþ
chemotherapy/chempotherapy/none)
1.15 (0.71–1.87) 0.573
Tumour stroma percentage (p50%/450%) 1.89 (1.26–2.82) o0.001 2.12 (1.37–3.29) 0.001
Systemic adjuvant therapy (n¼207)
Size (p20/21–50/450mm) 1.44 (0.96–2.15) 0.080 0.462
Grade (I/II/III) 1.66 (1.13–2.43) 0.010 0.256
Involved lymph node (0/1–3/43) 1.78 (1.31–2.40) o0.001 1.99 (1.41–2.82) o0.001
Oestrogen receptor status (no/yes) 0.47 (0.29–0.76) 0.002 0.181
Progesterone status (no/yes) 0.47 (0.27–0.83) 0.009 0.49 (0.26–0.89) 0.020
Lymphovascular invasion (no/yes) 1.99 (1.23–3.15) 0.003 0.160
Tumour necrosis (no/yes) 2.53 (1.41–4.52) 0.002 2.63 (1.40–4.96) 0.003
CD68þT-lymphocyte infiltrate (tertiles) 0.63 (0.46–0.86) 0.004 0.61 (0.43–8.44) 0.003
CD8þT-lymphocyte infiltrate (tertiles) 0.78 (0.56–1.03) 0.841
Loco-regional therapy (Lumpectomyþ radiotherapy/
mastectomyþ radiotherapy)
1.93 (1.15–3.26) 0.013 0.841
Tumour stroma percentage (p50%/450%) 2.04 (1.29–3.22) 0.002 1.86 (1.10–3.15) 0.021
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due to treatment regimen undertaken; though, in both studies
patients did not receive neoadjuvant treatment. Irrespective of this,
previous work has not determined whether the effect of an
expanded tumour stroma on survival was independent of host
inflammatory responses and other components of the tumour
microenvironment.
Although the inter-relationships between the tumour stroma,
tumour microenvironment and gross pathological characteristics
are likely complex, the TSP remained independently and strongly
associated with reduced cancer-specific survival. These results
confirm the importance of tumour-host factors, such as the
tumour microenvironment, in determining oncological outcome.
In particular, node-negative patients with high TSP had a more
than two-fold higher risk of breast cancer death compared with
those with low TSP, independent and comparable with that of
tumour size, lymph node status, grade and necrosis. Furthermore,
survival was also significantly shorter in patients who received
adjuvant therapy for high-TSP tumours. Thus, in addition to
identifying high-risk patients, TSP may also select patients less
likely to benefit from standard therapy and who should be
considered for additional adjunctive treatment, potentially targeted
at the stroma itself (Engels et al, 2012). These results confirm the
importance of tumour-host factors, such as the tumour micro-
environment in determining oncological outcome.
Table 7. The relationship between clinicopathological characteristics and cancer-specific survival in patients with node-negative breast cancer (n¼207)
Univariate analysis Multivariate analysis
Hazard ratio (95%
confidence interval) P-value
Hazard ratio (95%
confidence interval) P-value
Age (p50/450 years) 0.70 (0.36–1.36) 0.290
Size (p20/21–50/450mm) 2.32 (1.25–4.31) 0.007 2.47 (1.23–4.95) 0.011
Grade (I/II/III) 1.64 (0.97–2.73) 0.062 0.217
Oestrogen receptor status (no/yes) 0.71 (0.36–1.40) 0.325
Progesterone (no/yes) 0.75 (0.35–1.56) 0.437
Her2 status (no/yes) 2.11 (1.03–4.31) 0.040 0.306
Lymphovascular invasion (no/yes) 1.62 (0.78–3.38) 0.198
Tumour necrosis (no/yes) 1.97 (1.48–8.59) 0.005 2.51 (1.03–6.13) 0.043
General inflammatory infiltrate (low/high) 1.47 (0.76–2.86) 0.255
CD68þmacrophage infiltrate (tertiles) 0.68 (0.43–1.07) 0.096 0.313
CD4þT-lymphocyte infiltrate (tertiles) 0.88 (0.59–1.32) 0.520
CD8þT-lymphocyte infiltrate (tertiles) 0.89 (0.59–1.33) 0.558
Loco-regional therapy (Lumpectomyþ radiotherapy/
mastectomyþ radiotherapy)
2.11 (1.01–4.39) 0.047 0.188
Systemic adjuvant therapy (no/yes) 1.18 (0.57–2.42) 0.657
Tumour stroma percentage (p50%/450%) 2.24 (1.29–4.97) 0.005 3.11 (1.53–6.33) 0.002
Table 8. The relationship between clinicopathological characteristics and cancer-specific survival in patients with triple negative breast cancer (n¼151)
Univariate analysis Multivariate analysis
Hazard ratio (95%
confidence interval) P-value
Hazard ratio(95%
confidence interval) P-value
Age (p50/450 years) 1.23 (0.69–2.18) 0.475
Size (p20/21–50/450mm) 3.10 (1.91–5.04) o0.001 2.53 (1.52–4.21) o0.001
Involved lymph node (0/1–3/43) 1.91 (1.34–2.71) o0.001 1.64 (1.15–2.34) 0.007
Grade (I/II/III) 0.97 (0.54–1.74) 0.916
Lymphovascular invasion (no/yes) 2.11 (1.20–3.70) 0.009 0.337
Tumour necrosis (no/yes) 4.63 (1.66–12.88) o0.001 3.99 (1.43–11.13) 0.008
General inflammatory infiltrate (low/high) 0.84 (0.47–1.48) 0.534
CD68þmacrophage infiltrate (tertiles) 0.79 (0.54–1.16) 0.227
CD4þT-lymphocyte infiltrate (tertiles) 0.85 (0.60–1.19) 0.342
CD8þT-lymphocyte infiltrate (tertiles) 0.76 (0.55–1.05) 0.098 0.253
Loco-regional therapy (Lumpectomyþ radiotherapy/
mastectomyþ radiotherapy)
2.38 (1.24–4.58) 0.009 0.176
Adjuvant therapy (no/yes) 1.00 (0.48–2.02) 0.997
Tumour stroma percentage (p50%/450%) 1.06 (1.03–1.12) 0.035 0.151
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Despite recognition of the importance of the tumour stroma in
cancer progression, its relationship with other components of the
tumour microenvironment has yet to be fully characterised. In the
present study, increased amount of stroma was associated with a
weaker peritumoural inflammatory infiltrate, as measured by the
Klintrup–Ma¨kinen score and by macrophages and T-cell subtypes.
This is consistent with the recent observation that a high TSP
trended toward a low peritumoural inflammatory infiltrate in
patients with colorectal cancer (Park et al, 2014); however, the
underlying mechanism is still unclear. In the present study,
amount of tumour stroma was not associated with hormone
receptors or proliferative marker such as Ki67, although it
is of interest that Ki67 was recently shown to be significantly
associated with tumour inflammatory infiltrates (Mohammed et al,
2012a,b,c,d).
It has previously been proposed that the tumour stroma may
prevent effective tumour infiltration by immune cells (Ueno et al,
2004). The results from cell line experiments would also support
these findings, namely that fibroblasts and myofibroblasts can
modulate the ability of lymphocytes and macrophages to invade a
tumour and may prevent penetration of immune cells within
tumours, creating a physical barrier against an immune reaction
while promoting tumour growth and progression, due to their
contractile properties and their associated extracellular matrix
(Lieubeau et al, 1999).
In the present study, although the cell markers of both innate
and adaptive immune cells were examined in the present study, the
effect of TSP on survival remained independent of local
inflammatory responses, suggesting the presence of other mechan-
isms rather than a direct effect on immune cells. Indeed, tumour
stroma may promote the development of a pro-tumour rather than
anti-tumour immune infiltrate (Fridman et al, 2011). Stromal
fibroblasts may also induce suppression of the immune response
and produce immunosuppressive molecules such as TGF-b and
VEGF, suggesting that CAFs may promote cancer immunoescape
(Yaguchi et al, 2011; Engels et al, 2012). This may also implicate
certain cell signalling pathways such as the common cell signalling
pathway associated with inflammation; the JAK-State pathway
(Yu et al, 2007, 2009). Therefore, further characterisation of
the tumour inflammatory cell infiltrate and their association with
tumour stroma and JAK-State signalling is warranted.
In the present study, amount of tumour stroma was not
associated with hormone receptors or the proliferative marker
Ki67. However, it is of interest that the hormone receptors were
recently shown to be significantly associated with tumour
inflammatory infiltrates. Patients with high-grade general inflam-
matory infiltrate were more likely to have ER-negative and PR-
negative tumours. The expression of ER/PR was directly associated
with the percentage of tumour lymphocyte infiltrate and inversely
associated with CD68þ , CD8þ and CD138þ infiltrates.
Similarly, the expression of HER-2 was directly associated with
CD8þ and inversely associated with CD138þ infiltrates
(Baker et al, 2011; Mohammed et al, 2012c, 2013).
A potential limitation of the present study was that direct
investigation of the effect of tumour stroma on the infiltration of
inflammatory cells was not carried. This would require either cell
line or animal models. Although cell line or animal models do have
the advantage of allowing direct investigation of the effect of
tumour stroma on inflammatory cell infiltration, they often lack
clinical relevance to the patient with breast cancer with the
consequent slow progress on immunotherapy for breast cancer.
The present study highlights the importance of the amount of
tumour stroma on immunological response in patients with
primary operable ductal breast cancer.
In conclusion, the results of the present study show that a high
TSP in primary operable invasive ductal breast cancer was
associated with recurrence and shorter long-term survival.
Implementing this simple and reproducible parameter in routine
pathological examination may help optimise risk stratification in
patients with invasive ductal breast cancer. The present study
findings suggest that high TSP enables tumour cells to evade the
immune response and promote tumour progression.
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